Compagnie Lombard Odier SCmA Purchases 15,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Compagnie Lombard Odier SCmA boosted its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 286.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,245 shares of the biotechnology company's stock after purchasing an additional 15,000 shares during the period. Compagnie Lombard Odier SCmA's holdings in Viking Therapeutics were worth $489,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Bank Julius Baer & Co. Ltd Zurich raised its position in shares of Viking Therapeutics by 7.4% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,980 shares of the biotechnology company's stock worth $221,000 after acquiring an additional 345 shares during the last quarter. Arizona State Retirement System raised its stake in Viking Therapeutics by 1.2% during the fourth quarter. Arizona State Retirement System now owns 28,929 shares of the biotechnology company's stock worth $1,164,000 after buying an additional 353 shares during the last quarter. WealthTrust Asset Management LLC raised its stake in Viking Therapeutics by 6.7% during the fourth quarter. WealthTrust Asset Management LLC now owns 6,923 shares of the biotechnology company's stock worth $279,000 after buying an additional 437 shares during the last quarter. Parallel Advisors LLC raised its stake in Viking Therapeutics by 64.8% during the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock worth $33,000 after buying an additional 536 shares during the last quarter. Finally, Xponance Inc. raised its position in shares of Viking Therapeutics by 4.5% in the 4th quarter. Xponance Inc. now owns 14,024 shares of the biotechnology company's stock worth $564,000 after acquiring an additional 610 shares in the last quarter. 76.03% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Viking Therapeutics

In other Viking Therapeutics news, Director Sarah Kathryn Rouan acquired 1,240 shares of the company's stock in a transaction that occurred on Monday, March 31st. The stock was bought at an average price of $24.15 per share, with a total value of $29,946.00. Following the completion of the purchase, the director now owns 1,240 shares of the company's stock, valued at approximately $29,946. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.10% of the company's stock.

Wall Street Analyst Weigh In

VKTX has been the subject of a number of research analyst reports. Morgan Stanley lowered their target price on Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Truist Financial restated a "buy" rating and set a $75.00 price target (down previously from $95.00) on shares of Viking Therapeutics in a research note on Monday, April 28th. Cantor Fitzgerald upgraded shares of Viking Therapeutics to a "strong-buy" rating in a research note on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a report on Thursday, April 24th. Finally, The Goldman Sachs Group initiated coverage on Viking Therapeutics in a report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Viking Therapeutics has an average rating of "Moderate Buy" and an average target price of $87.15.

Viking Therapeutics Price Performance

Shares of Viking Therapeutics stock traded up $0.88 during trading hours on Monday, reaching $26.96. The company had a trading volume of 2,984,248 shares, compared to its average volume of 4,060,355. Viking Therapeutics, Inc. has a one year low of $18.92 and a one year high of $81.73. The business has a fifty day simple moving average of $26.60 and a 200 day simple moving average of $31.68. The firm has a market cap of $3.03 billion, a PE ratio of -26.96 and a beta of 0.65.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). During the same quarter in the prior year, the company posted ($0.26) EPS. The firm's revenue for the quarter was up .0% compared to the same quarter last year. On average, research analysts forecast that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.